Baqsimi (glucagon), first non-injectable treatment for severe low blood sugar levels
EMA’s human medicines committee (CHMP) has recommended granting a marketing…
Reyvow (lasmiditan), new treatment for patients with migraine
The U.S. Food and Drug Administration has approved Reyvow (lasmiditan) tablets…
Trikafta (elexacaftor/ivacaftor/tezacaftor), new breakthrough therapy for cystic fibrosis
The U.S. Food and Drug Administration has approved Trikafta…
Mavyret (glecaprevir and pibrentasvir), a treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis, shortens the duration of treatment to eight weeks
Mavyret (glecaprevir and pibrentasvir) tablets, have now been approved by the…
Rybelsus (semaglutide), first oral GLP-1 treatment for type 2 diabetes
The U.S. Food and Drug Administration has approved Rybelsus (semaglutide) oral…
Ofev (nintedanib), first treatment for patients with rare type of lung disease
The U.S. Food and Drug Administration has approved Ofev (nintedanib) capsules…
Nourianz (istradefylline), new add-on drug to treat off episodes in adults with Parkinson’s disease
The U.S. Food and Drug Administration has approved Nourianz (istradefylline)…
Xenleta (lefamulin), new antibiotic to treat community-acquired bacterial pneumonia
The U.S. Food and Drug Administration has approved Xenleta (lefamulin) to treat…
Inrebic (fedratinib) capsules, new treatment for adult patients with certain types of myelofibrosis
The U.S. Food and Drug Administration has approved Inrebic (fedratinib)…
Pretomanid, new drug for the treatment of tuberculosis that affects the lungs
The U.S. Food and Drug Administration has approved Pretomanid Tablets in…